神经刺激疗法研发商Neuros Medical获得5600万美元D轮融资，用于将FDA批准的非阿片类神经刺激系统Altius® System商业化，该系统用于治疗慢性截肢后疼痛-动脉网

Neuros Medical Secures $56M Series D to Commercialize the Altius® System, an FDA-Approved, Non-Opioid Nerve Stimulation System for Chronic Post-Amputation Pain

CISION 等信源发布 2025-07-09 19:59



可切换为仅中文







ALISO VIEJO, Calif.

加利福尼亚州阿利索维耶霍

，

July 9, 2025

2025年7月9日

/PRNewswire/ -- Neuros Medical, Inc., the maker of the Altius

/PRNewswire/ -- Neuros Medical, Inc.，Altius 的制造商

Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, today announced the closing of an oversubscribed

直接电神经刺激系统，一种经FDA批准的、突破性的非阿片类治疗慢性截肢后疼痛的方法，今天宣布了一项超额认购的结束。

$56 million

5600万美元

Series D financing round. The funding will support U.S. commercialization and further development of its groundbreaking Altius

D轮融资。这笔资金将支持其在美国的商业化进程，并进一步推动其突破性的Altius技术的发展。

Direct Electrical Nerve Stimulation System.

直接电神经刺激系统。

The round was led by new investor EQT Life Sciences, with participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners and several long-standing and committed investors.

本轮融资由新投资者EQT生命科学领投，现有投资者也参与其中，包括美国风险合伙人、Amzak健康、奥斯大学合作伙伴、行业资产管理、光圈风险合伙人以及几位长期且坚定的投资者。

'I would like to thank our new and existing investors for their support in our mission to relieve pain and restore life for the millions of people suffering from chronic post-amputation pain,' said

“我要感谢我们的新投资者和现有投资者对我们使命的支持，即缓解疼痛，恢复数百万遭受慢性截肢后疼痛的患者的生活，”他说。

David Veino

大卫·维诺

, President & CEO, Neuros Medical. 'This funding round is a strong validation of the unmet medical need in the amputee community and allows us to scale our commercial operations to expand access to this breakthrough technology, while equipping healthcare professionals with a non-opioid solution and support they need to deliver the highest standard of care.'.

，总裁兼首席执行官，Neuros Medical。 “这一轮融资是对截肢者社区未满足的医疗需求的有力验证，使我们能够扩大商业运营规模，以扩大对该突破性技术的获取，同时为医疗保健专业人员提供他们所需的非阿片类解决方案和支持，以提供最高标准的护理。”

Fouad Azzam

福阿德·阿扎姆

, Ph.D., Partner in the EQT Life Sciences advisory team, commented: 'Neuros Medical is addressing one of the most urgent and overlooked challenges in chronic pain management. EQT believes Altius has the potential to significantly improve the quality of life for amputees, and we are proud to partner with this team to bring the therapy to market.' .

博士，EQT生命科学顾问团队的合伙人评论道：“Neuros Medical正在应对慢性疼痛管理中最紧迫且被忽视的挑战之一。EQT相信Altius有潜力显著改善截肢者的生活质量，我们很自豪能与这个团队合作将这种疗法推向市场。”

About the Altius

关于Altius

Direct Electrical Nerve Stimulation System

直接电神经刺激系统

The Altius

阿尔提乌斯

System is a patient-controlled, on-demand system that uses Neuros' patented technology to address the underlying cause of post-amputation pain by inhibiting pain signal transmission from the damaged peripheral nerves near the site of amputation to the central nervous system. The system consists of a nerve cuff electrode placed around an affected nerve and an implantable pulse generator (IPG).

系统是一种由患者控制、按需使用的系统，利用Neuros的专利技术，通过抑制从截肢部位附近受损的外周神经向中枢神经系统传递疼痛信号，来解决截肢后疼痛的根本原因。该系统包括一个放置在受影响神经周围的神经袖带电极和一个可植入脉冲发生器 (IPG)。

Patients initiate an on-demand 30-minute treatment session as needed for targeted pain relief..

患者根据需要启动按需的30分钟治疗疗程，以获得针对性的疼痛缓解。

The Altius System is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. The Altius System is the only FDA-approved device that provides amputees with patient-controlled, on-demand relief by targeting the nerve pain directly..

Altius系统已获FDA批准，适用于帮助管理成年截肢者因下肢截肢后出现的慢性顽固性幻肢痛和残肢痛。Altius系统是唯一获得FDA批准的设备，能够通过直接针对神经疼痛，为截肢者提供患者自控、按需缓解疼痛的功能。

Click here for important safety information.

点击此处获取重要的安全信息。

About Neuros Medical, Inc.

关于Neuros Medical公司

There are nearly two million amputees in the U.S., with 300,000 new amputations occurring every year.

美国有近两百万截肢者，每年新增三十万例截肢手术。

Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.

截肢后疼痛包括幻肢痛和残肢痛，影响高达80%的截肢者，代表了一个重要的未满足医疗需求，因为现有的治疗选择有限，主要由阿片类药物和加巴喷丁类药物组成。

Neuros Medical is a privately held company and the maker of the Altius

Neuros Medical是一家私营公司，也是Altius的制造商。

Direct Electrical Nerve Stimulation System which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to reduce pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them..

经FDA批准的直接电神经刺激系统，适用于成人截肢者慢性难治性幻肢痛和残肢痛的辅助管理。我们的使命是减轻术后截肢疼痛患者的痛苦，恢复他们的生活。我们是一个由核心价值观引导的充满热情的团队，致力于为患者以及照顾他们的医疗保健专业人员提供支持。

Our Core Values: Patients First, Deliver Excellence, Responsible Ambition, Inspire and Empower.

我们的核心价值观：患者至上、追求卓越、负责任的雄心、激励与赋能。

References

参考文献

1. Prevalence of Limb Loss and Limb Difference in

1. 肢体丧失和肢体差异的普遍性

the United States

美国

: Implications for Public Policy. Caruso and Harrington 2024 Avelere Report.

：对公共政策的影响。卡鲁索和哈林顿 2024 年阿维莱尔报告。

2. Erlenwein, J., Diers, M., Ernst, J., Schulz, F., & Petzke, F. (2021). Clinical updates on phantom limb pain. Pain reports, 6(1), e888.